Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.Novartis AG Key Recent Developments
- Apr 23, 2024: Novartis Delivers Double-Digit Sales Growth and Core Margin Expansion in Q1, Fy 2024 Guidance Raised
- Apr 12, 2024: Novartis signs deal for Arvinas’ prostate cancer therapy
- Mar 15, 2024: Novartis Expands Its Biopharmaceutical Manufacturing Site in Singapore
- Mar 14, 2024: Biotech's Role in Addressing the Pancreatic Cancer Emergency
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- AbbVie Inc
- Pfizer Inc
- Verona Pharma Plc
- Novo Nordisk AS
- GSK plc
- Takeda Pharmaceutical Co Ltd
- SELLAS Life Sciences Group Inc
- Merck & Co Inc
- Biogen Inc
- Amgen Inc
- Sanofi
- Bristol-Myers Squibb Co
- Gilead Sciences Inc
- Eli Lilly and Co
- SELLAS Life Sciences Group Inc
- Generex Biotechnology Corp
- AstraZeneca Plc
- Acceleron Pharma Inc
- F. Hoffmann-La Roche Ltd
- GW Pharmaceuticals Plc
- GSK plc
- Johnson & Johnson
- Flarer SA
- AbbVie Inc
- Bristol-Myers Squibb Co
- Addex Therapeutics Ltd
- Yumanity Therapeutics Inc
- Antion Biosciences SA
- Cassava Sciences Inc
- Sanofi
- Eli Lilly and Co
- Takeda Pharmaceutical Co Ltd
- Merck & Co Inc
- Curis Inc
- Pfizer Inc
- Verona Pharma Plc
- Novo Nordisk AS
- Kuros Biosciences AG